A group of researchers from Politecnico di Milano, coordinated by Prof. Luca Mainardi of the Department of Electronics, Information and Bioengineering, will take part in EXIT-CVD, a European research project dedicated to cardiovascular disease.
Over the next five years, the project will involve more than 14,000 patients across 22 clinical studies, with the aim of identifying new strategies to prevent, slow down or halt the progression of heart disease. Co-funded by the European Union’s Innovative Health Initiative, EXIT-CVD brings together 42 public and private partners from 17 countries, including universities, hospitals, pharmaceutical and biomedical companies, scientific associations and patient organisations.
The project combines complementary research approaches, ranging from early diagnosis through artificial intelligence and wearable devices to advanced imaging techniques and regenerative therapies. Alongside clinical research, it will also examine the economic sustainability and accessibility of these innovations, with the goal of supporting their implementation across European healthcare systems.
Thanks to its pan-European scope and the collaboration between public research and industry, EXIT-CVD will address cardiovascular disease throughout the entire care pathway. It will bring together clinical, technological and economic expertise, while paying particular attention to social and gender inequalities, as well as disparities in digital access.
As part of the project, Politecnico di Milano will develop artificial intelligence-based algorithms for the analysis of ECG, blood pressure and photoplethysmographic signals, as well as for multisensor data fusion, with the aim of enabling the early detection of ischaemia. The University will also contribute to the COMPASS study, which focuses on postpartum blood pressure monitoring via smartwatch in women who experienced hypertensive disorders during pregnancy.
This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101253160. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bío, MedTech Europe and Vaccines Europe.
